IL318532A - IL-15 inhibitors are useful for treating atopic dermatitis - Google Patents
IL-15 inhibitors are useful for treating atopic dermatitisInfo
- Publication number
- IL318532A IL318532A IL318532A IL31853225A IL318532A IL 318532 A IL318532 A IL 318532A IL 318532 A IL318532 A IL 318532A IL 31853225 A IL31853225 A IL 31853225A IL 318532 A IL318532 A IL 318532A
- Authority
- IL
- Israel
- Prior art keywords
- treatment
- atopic dermatitis
- inhibitors useful
- inhibitors
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22188873 | 2022-08-04 | ||
| PCT/EP2023/071573 WO2024028448A1 (en) | 2022-08-04 | 2023-08-03 | Il-15 inhibitors useful for the treatment of atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL318532A true IL318532A (en) | 2025-03-01 |
Family
ID=82839400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL318532A IL318532A (en) | 2022-08-04 | 2023-08-03 | IL-15 inhibitors are useful for treating atopic dermatitis |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4565327A1 (de) |
| JP (1) | JP2025525860A (de) |
| KR (1) | KR20250044344A (de) |
| CN (2) | CN119698301A (de) |
| AU (1) | AU2023317825A1 (de) |
| CA (1) | CA3263439A1 (de) |
| CL (1) | CL2025000306A1 (de) |
| DO (1) | DOP2025000017A (de) |
| IL (1) | IL318532A (de) |
| JO (1) | JOP20250024A1 (de) |
| MA (1) | MA71681A (de) |
| MX (1) | MX2025001337A (de) |
| WO (1) | WO2024028448A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025227052A1 (en) | 2024-04-26 | 2025-10-30 | Cephalon Llc | Doses and formulations of anti-il-15 antibody for the treatment of immune diseases |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160358A0 (en) | 2001-08-23 | 2004-07-25 | Genmab As | Human antibodies specific for interleukin 15 (il-15) |
| US20050123542A1 (en) | 2003-11-06 | 2005-06-09 | Genmab A/S | Methods for treating disorders involving monocytes |
| CU23472A1 (es) | 2004-09-17 | 2009-12-17 | Ct Ingenieria Genetica Biotech | Péptido antagonista de la interleucina-15 |
| CA2691785C (en) | 2007-06-27 | 2017-01-10 | Marine Polymer Technologies Inc. | Complexes of il-15 and il-15ralpha and uses thereof |
| US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| EP2963057A1 (de) | 2014-07-02 | 2016-01-06 | Calypso Biotech SA | Antikörper zu IL-15 |
| EP3359556B1 (de) | 2015-10-09 | 2021-05-26 | Bioniz, LLC | Modulation der gamma-c-zytokin-aktivität |
| CN109311972A (zh) | 2016-06-15 | 2019-02-05 | 美国安进公司 | 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物 |
| US20180002417A1 (en) | 2016-06-15 | 2018-01-04 | Celimmune Llc | Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease |
| RS66900B1 (sr) | 2016-12-21 | 2025-07-31 | Cephalon Llc | Antitela koja se specifično vezuju za humani il-15 i njihova upotreba |
| JP2022530677A (ja) | 2019-05-03 | 2022-06-30 | バイオニズ リミテッド ライアビリティー カンパニー | 脱毛症および脱毛症関連障害の治療ための、γｃサイトカインのシグナル伝達の効果の調節 |
-
2023
- 2023-08-03 CN CN202380056686.3A patent/CN119698301A/zh active Pending
- 2023-08-03 KR KR1020257006137A patent/KR20250044344A/ko active Pending
- 2023-08-03 EP EP23751966.5A patent/EP4565327A1/de active Pending
- 2023-08-03 IL IL318532A patent/IL318532A/en unknown
- 2023-08-03 AU AU2023317825A patent/AU2023317825A1/en active Pending
- 2023-08-03 JP JP2025505748A patent/JP2025525860A/ja active Pending
- 2023-08-03 WO PCT/EP2023/071573 patent/WO2024028448A1/en not_active Ceased
- 2023-08-03 MA MA71681A patent/MA71681A/fr unknown
- 2023-08-03 CN CN202511082665.6A patent/CN120899897A/zh active Pending
- 2023-08-03 CA CA3263439A patent/CA3263439A1/en active Pending
-
2025
- 2025-01-30 JO JOJO/P/2025/0024A patent/JOP20250024A1/ar unknown
- 2025-01-31 MX MX2025001337A patent/MX2025001337A/es unknown
- 2025-01-31 CL CL2025000306A patent/CL2025000306A1/es unknown
- 2025-01-31 DO DO2025000017A patent/DOP2025000017A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2025000017A (es) | 2025-04-15 |
| WO2024028448A1 (en) | 2024-02-08 |
| JP2025525860A (ja) | 2025-08-07 |
| CN120899897A (zh) | 2025-11-07 |
| CN119698301A (zh) | 2025-03-25 |
| JOP20250024A1 (ar) | 2025-01-30 |
| CL2025000306A1 (es) | 2025-06-13 |
| MX2025001337A (es) | 2025-03-07 |
| EP4565327A1 (de) | 2025-06-11 |
| KR20250044344A (ko) | 2025-03-31 |
| MA71681A (fr) | 2025-05-30 |
| AU2023317825A1 (en) | 2025-02-13 |
| CA3263439A1 (en) | 2024-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308195A (en) | RAS inhibitors for cancer treatment | |
| IL308476A (en) | Inhibitors of the menin-mil interaction | |
| GB202416189D0 (en) | Methods for the prophylaxis and treatment of Covid and Covid-19 | |
| IL310701A (en) | Treatment of atopic dermatitis | |
| IL315503A (en) | Treatment methods | |
| IL320711A (en) | Treatment methods | |
| CA3263439A1 (en) | IL-15 INHIBITORS USEFUL FOR THE TREATMENT OF ATOPIC DERMATITIS | |
| GB202201824D0 (en) | Methods of treatment | |
| HK40122865A (en) | Il-15 inhibitors useful for the treatment of atopic dermatitis | |
| EP4444419A4 (de) | Verfahren zur behandlung von lymphödemen | |
| IL307291A (en) | Methods for treating inflammation | |
| GB202201825D0 (en) | Methods of treatment | |
| GB202201819D0 (en) | Methods of treatment | |
| PL3941465T3 (pl) | Sposoby leczenia zespołu nadpobudliwości psychoruchowej z deficytem uwagi z zastosowaniem inhibitorów kdm1a, takich jak związek wafidemstat | |
| IL326251A (en) | Treatment of atopic dermatitis | |
| GB202204291D0 (en) | Treatment of atopic dermatitis | |
| GB202204211D0 (en) | Treatment of atopic dermatitis | |
| GB202115152D0 (en) | Treatment of atopic dermatitis | |
| IL308377A (en) | Methods for treating skin and muscle inflammation | |
| IL271778A (en) | Methods for treating atopic dermatitis | |
| HK40112475A (zh) | 特应性皮炎的治疗 | |
| HK40089188A (en) | Methods of treating dermatomyositis | |
| GB2603967B (en) | Methods for determining the effectiveness of plant control treatment | |
| HK40117615A (en) | Compositions and methods for treatment of epilepsies | |
| CA3300416A1 (en) | Treatment of atopic dermatitis |